glp 1 and 2 drugs GLP-1 from the Gray Market GLP-1 RAs, Other Agents, Underused

The current cycle began in 2014 and hit a contraction phase in 2020 that has continued since, thanks in large part to drought

Available from: Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J

Researchers who add too many variables simultaneously cannot identify which compound is producing which effect, making troubleshooting impossible

+ 1.0 kg with placebo [26]

During GLP-1 treatment , maintain regular contact with your healthcare team and report: Any new or worsening anxiety symptoms , including excessive worry, panic attacks, or physical anxiety symptoms Changes in mood , sleep patterns, or appetite beyond expected treatment effects Difficulty coping with side effects such as nausea, which may exacerbate anxiety Concerns about body image or eating behaviours as weight changes occur NICE guidance recommends holistic care for people with diabetes and obesity, recognising the importance of psychological wellbeing

92 In the subgroup analysis by preserved versus reduced LVEF, there was no difference between treatment and placebo